Seroprevalence of ıgg antibodies against mumps in bulgarian children under 18 years of age

Objective: The objective of this study was to determine the prevalence of IgG antibodies against mumps in a representative stratified sample of children under 18 years of age in Pleven district, Bulgaria. Study Design: Cross sectional study. Materials and Methods: A cross-sectional, sero-epidemiologic survey of 132 children aged under 18 years was conducted in Pleven district. They were distributed into two age groups: from 0 to 11 years old (n=80) and from 12 to 18 years old (n=52). An enzyme immunoassay (EIA) was performed for indirect evidence of specific IgG antibodies in the serum. Results: The results showed that 41% of the investigated children were negative in terms of mumps IgG antibodies, 11% had borderline values and the remaining, approximately 48%, were positive. In the group of children aged 0 to 11 years who had received one dose of the mumps vaccine, 50% were negative for mumps IgG antibodies. In the second group of children aged 12 to 18 years who had received two vaccine doses, the percentage of partici- pants negative for mumps IgG antibodies decreased significantly. Conclusion: Our observations emphasise the need to conduct expanded sero-epidemiological investigations of the populations most affected by mumps and to immunise susceptible individuals.

PDF

___

1. Karcheva M. Survey on efficiency of mass specific immune pro- phylactics at mumps. Summary of Dissertation. 2010;1-65.
2. Amanna IJ, Nichole EC, Mark KS. Duration of humoral im- munity to common viral and vaccine antigens. N Engl J Med 2007;357:1903-15. [CrossRef]
3. Dominguez A, Plans P, Costa J, Torner N, Cardenosa N, Batalla J, et al. Seroprevalence of measles, rubella, and mumps antibodies in Catalonia, Spain:results of a cross-sectional study. Eur J Clin Microbiol Infect Dis 2006;25:310-7. [CrossRef]
4. Desgrandchamps D, Schaad UB, Glaus J, Tusch G, Heininger U. Seroprevalence of IgG antibodies against measles, mumps and rubella in Swiss children during the first 16 months of life. Sch- weizerische Medizinische Wochenschrift 2000;130:1479-86.
5. Gürgöze MK, Yilmaz E, Gödekmerdan A, Akça Z, Doğan Y, Akar- su S, et al. Seroprevalence of mumps, varicella and rubella an- tibodies in children 1-16 years of age in eastern Turkey. Turk J Pediatr 2006;483:185-8.
6. Sáenz González MC, Núñez Mateos JC, Rodrigo Sánchez N, Mar- tín Sánchez AM. Sero-epidemiologic study of measles, rubella and mumps in the infantile population of Salamanca. An Esp Pe- diatr 1992;36:293-7.
7. Socan M, Berginc N. High seroprevalence of varicella, measles, mumps, rubella and pertussis antibodies in first-grade medical students. Wien Klin Wochenschr 2008;120:422-6. [CrossRef]
8. Odiseev H. Specific immuno prophylactics of mumps with live vaccine-strain, Sofia 6. Summary of Dissertation 1970;1-74.
9. Odiseev H. Surveys on mumps in Bulgaria. Summary of Disserta- tion 1976;1-76.
10. Eriksen J, Davidkin I, Kafatos G, Andrews N, Barbara C, Cohen D, et al. Seroepidemiology of mumps in Europe (1996-2008):why do outbreaks occur in highly vaccinated populations? Epidemiol Infect 2012;12:1-16.
11. Muhsen Kh, Aboudy Y, Mendelson E, Green MS, Cohen D. Preva- lence of mumps antibodies in the Israeli population in relation to mumps vaccination policy and incidence of disease. Epidemiol Infect 2008;136:688-93. [CrossRef]
12. Stohrer-Draxl P, Amstad H, Grize L, Gassner M, Takken-Sahli K, Bourquin C, et al. Measles, mumps and rubella:vaccination rate and seroprevalence in 8th grade students of 8 different sites in Switzerland 1995/96. Schweiz Runsch Med Prax 1999;88:1069-77.
13. Zäch K, Nicoara C, Germann D, Matter L. Age-related seropreva- lence of measles, mumps and rubella antibodies in 1996. Schweiz Med Wochenschr 1998;128:649-57.